Data Sheet 3_Transcriptomics, identification, and testing of manganese metabolism-related genes in cervical squamous cell carcinoma.csv

Associations with immune infiltration, drug sensitivity, and clinical features were further investigated. Experimental validation was performed using real-time quantitative polymerase chain reaction, western blotting, and immunofluorescence staining in CSCC and normal cervical cells.</p>Results<p>A four-gene prognostic signature (PARP1, SLC20A1, GALNTL6, and TAGLN) was established. Patients were stratified into high- and low-risk groups, and survival was significantly worse in the high-risk group (p = 0.0034).

The risk model demonstrated good predictive performance (1-/2-/3-year area under the curve = 0.72/0.76/0.83), and its performance was externally validated in an independent cohort. Notably, risk stratification was associated with distinct immune infiltration patterns (including natural killer cells and regulatory T cells), focal adhesion pathway enrichment, and differential drug sensitivity. A nomogram incorporating the risk score, race, and lymphovascular invasion exhibited improved prognostic stratification.</p>Conclusion<p>This study presents the first MAM-related prognostic signature specifically tailored to CSCC, filling a gap in existing prognostic models that did not consider the role of MAM.

The four-gene risk model offers a robust tool for patient stratification, with potential implications for guiding personalized immunotherapy and targeted therapy. These findings provide a novel framework for incorporating metabolic perspectives into CSCC prognosis and warrant further clinical validation.</p>